VRTX · Vertex Pharmaceuticals Inc · Documents
$523.93
-11.24 (-2.10%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$132.80B
Shares
253.46M
Volume · Oct 23
833.46K
Avg daily vol (3M)
1.18M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| Investor Event Transcript | Vertex Pharmaceuticals reported that povitacicept achieved a 52% proteinuria reduction at 36 weeks in IgA nephropathy, with a November 30th PDUFA date, while the fully enrolled Amplitude trial of 522 patients is expected to report interim results early next year. | 2026-10-24 | 2026-12-31 | |
| 8-K | Vertex Pharmaceuticals Incorporated appointed Daniel Brennan to its board on October 20, 2026, increasing the board from ten to eleven members; he joined the Audit and Finance Committee and received a $400,000 restricted stock unit award vesting in October 2027. | 2026-10-20 | — | |
| Investor Event Transcript | — | 2026-09-23 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-09 | 2026-09-30 | |
| 8-K | — | 2026-09-01 | 2026-08-27 | |
| 10-Q | — | 2026-08-04 | 2026-06-30 | |
| 8-K | — | 2026-08-03 | — | |
| 8-K | — | 2026-07-07 | 2026-07-06 | |
| Investor Event Transcript | — | 2026-07-06 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-06-30 | — | |
| Investor Event Transcript | — | 2026-06-10 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-10 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-29 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-19 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-19 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-19 | 2026-06-30 | |
| 8-K | — | 2026-05-13 | — | |
| 10-Q | — | 2026-05-05 | 2026-03-31 | |
| 8-K | — | 2026-05-04 | — | |
| 8-K | — | 2026-04-29 | 2026-04-28 | |
| DEFA14A | — | 2026-04-29 | — | |
| DEFA14A | — | 2026-04-02 | — | |
| DEF 14A | — | 2026-04-02 | 2026-05-13 | |
| ARS | — | 2026-04-02 | 2025-12-31 | |
| Investor Event Transcript | — | 2026-03-31 | — | |
| 8-K | — | 2026-03-31 | — | |
| Investor Event Transcript | — | 2026-03-11 | 2026-03-31 | |
| 10-K | — | 2026-02-13 | 2025-12-31 | |
| 8-K | — | 2026-02-12 | — | |
| 10-Q | — | 2025-11-04 | 2025-09-30 | |
| 8-K | — | 2025-11-03 | — | |
| 10-Q | — | 2025-08-05 | 2025-06-30 | |
| 8-K | — | 2025-08-04 | — | |
| 8-K | — | 2025-05-19 | — | |
| 8-K | — | 2025-05-14 | — | |
| 10-Q | — | 2025-05-06 | 2025-03-31 | |
| 8-K | — | 2025-05-05 | — | |
| ARS | — | 2025-04-03 | 2024-12-31 | |
| DEF 14A | — | 2025-04-03 | 2025-05-14 | |
| DEFA14A | — | 2025-04-03 | — | |
| 8-K | — | 2025-03-28 | — | |
| 10-K | — | 2025-02-13 | 2024-12-31 | |
| S-3ASR | — | 2025-02-13 | — | |
| 8-K | — | 2025-02-10 | 2025-02-04 | |
| 8-K | — | 2024-12-20 | — | |
| 10-Q | — | 2024-11-05 | 2024-09-30 | |
| 8-K | — | 2024-11-04 | — | |
| 8-K | — | 2024-08-16 | 2024-08-15 | |
| 10-Q | — | 2024-08-02 | 2024-06-30 | |
| 8-K | — | 2024-08-01 | — |
Showing 1–50 of 126 filings
Key facts
CIK
875320
CUSIP
92532F100
13F (30d)
508 filings
485 filers
Visit website
Investor relations